Bluejay Diagnostics Announces Closing of $4.5 Million Private Placement Priced At-The-Market Under Nasdaq Rules

ACTON, Mass., Oct. 10, 2025 (GLOBE NEWSWIRE) -- Bluejay Diagnostics, Inc. (NASDAQ: BJDX) (“Bluejay” or the “Company”), a medical diagnostics company developing near-patient solutions for critical care, today announced the closing of its previously announced private placement for the purchase and sale of an aggregate of 2,250,000 shares of common stock (or pre-funded warrants in lieu thereof) and Series F warrants to purchase up to 4,500,000 shares of common stock at a purchase price of $2.00 per share of common stock (or per pre-funded warrant in lieu thereof) and accompanying warrants priced at-the-market under Nasdaq rules. The Series F warrants have an exercise price of $1.75 per share and are exercisable immediately upon issuance. The Series F warrants expire five and one-half years from the date of issuance.

Read more at globenewswire.com